Lv1
28 积分 2024-12-24 加入
P77.01 Preliminary Data from QUILT 3.055: A Phase 2 Multi-Cohort Study of N803 (IL-15 Superagonist) in Combination with Checkpoint Inhibitors in NSCLC
1天前
待确认
Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network
1个月前
已完结
Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population
1个月前
已完结
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
4个月前
已完结
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
4个月前
已完结
Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
4个月前
已完结
Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design
4个月前
已完结
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
5个月前
已完结
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
6个月前
已完结
Intravesical therapy with the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab is well tolerated and shows encouraging preliminary efficacy in patients with high-risk
6个月前
已完结
皖公网安备34019202002308
